电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Collagen IV 抗体

This anti-Collagen IV antibody is a 山羊 多克隆 antibody detecting Collagen IV in ELISA. Suitable for 人. This Primary Antibody has been cited in 21+ publications.
产品编号
发货至: 中国

Quick Overview for Collagen IV 抗体 ()

抗原

See all Collagen IV (COL4) 抗体
Collagen IV (COL4) (Collagen, Type IV (COL4))

适用

  • 96
  • 47
  • 39
  • 22
  • 17
  • 12
  • 2
  • 2

宿主

  • 65
  • 28
  • 11
山羊

克隆类型

  • 74
  • 30
多克隆

标记

  • 47
  • 11
  • 7
  • 6
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This Collagen IV antibody is un-conjugated

应用范围

  • 64
  • 47
  • 35
  • 32
  • 30
  • 26
  • 26
  • 24
  • 15
  • 11
  • 9
  • 9
  • 5
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
ELISA
  • Key Features

    • Frequently cited in scientific publications with 300+ citations
    • Validated inhouse for relevant applications
    • Extensive validation report for IF provided by one of your peers
    • Designed to detect RFP and its variants

    Key Features

    • Multiplex ELISA: Testing 5 Targets in 1 Run
    • High performance COVID-19 antibody testing
    • 99.6% specificity, 95.9% sensitivity

    Key Features

    • Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
    • Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), B.1.1.529 (omicron), B.1.429 (epsilon), B.1.525 (eta), and B.1.617.1 (kappa).
    • Frequently used as reference in S-protein ELISAs and neutralization assays.
    • Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.

    Key Features

    • Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
    • Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), and B.1.525 (eta).
    • Frequently used as reference in S-protein ELISAs and neutralization assays.
    • Synergizes with other hNAbs: binds a highly conserved epitope.
    • No interference with the ACE2 binding site.

    Key Features

    • Dendra2 Antibody (ABIN361314) independently validated for Immunocytochemistry by Neurology Lab (INSERM).
    • Publications cite use for Immunoblotting as well as Immunostaining.
    • Dendra2 belongs to a new class of photoactivatable fluorescent proteins (PAFPs). PAFPs allow to photolable and track fusion proteins in vivo. Dendra2 Antibody (ABIN361314) can be used for control purposes in this setting.

    Key Features

    • Magnetic agarose concanavalin A beads for CUT&RUN and CUT&Tag assays.
    • Superior handling compared to magnetic silica concanavalin A beads: easier washes and resuspension.
    • Reduced risk for samples to dry out.
    • Performance comparable to or better than magnetic silica concanavalin A beads.

    Key Features

    • Recombinant SARS-CoV-2 spike protein produced in HEK-293.
    • Contains the E484K mutation (present in the novel lineage 501Y.S2 from South Africa) that can affect antibody recognition and enable SARS-CoV-2 immune escape.
    • Contains the D614G mutation that renders SARS-CoV-2 infection and replication more efficient.

    Key Features

    • Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
    • Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.

    Key Features

    • Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
    • Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.

    Key Features

    • Simultaneous detection of Sp Cas9 binding and cleavage sites in genomic DNA.
    • In situ assay leaves cells intact and reduces background.
    • Unbiased detection of off-site effects because it is not based on a predictive algorithm.

    Key Features

    • Detection of SARS-CoV-2 with variety of different immunoassays, i.e. ELISA, Lateral Flow, as validated by numerous publications (see below).
    • Nucleocapsid antibody used for diagnostic Covid19 testing as well as for drug discovery.
    • Developed and manufactured in the U.S.

    Key Features

    • Has been shown to neutralize SARS-Cov-2 S protein RBD from lineages B.1.1.7, B.1.351, P.1, and B.1.429.
    • Suitable as positive control in neutralization antibody screening.
    • Humanized chimeric antibody consisting of human IgG1 constant domains and murine variable regions.

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
    • Contains E154K, L452R, E484Q, D614G, and P681R mutations characteristic for the SARS-CoV-2 kappa variant (B.1.617.1).

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.525.
    • Contains Q52R, del 69-70, del 144, E484K, F888L, and Q677H mutations characteristic for the SARS-CoV-2 eta variant (B.1.525).

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.429.
    • Contains S13I, W152C, L452R, and D1183Y mutations characteristic for the SARS-CoV-2 eta variant (B.1.429).

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.7.
    • Contains del 69-70, del 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H mutations characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of concern P.1.
    • Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
    • Contains T19R, L452R, T478K, D614G, P681R and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.621 mu.
    • Contains T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H and D950N mutations characteristic for the SARS-CoV-2 mu variant (B.1.621).

    Key Features

    • NLRP3 antibody for reliable recognition of mouse and human NLRP3/NALP3
    • This un-conjugated monoclonal antibody has 60 PubMed citations

    Key Features

    • 95+ publication references, 1 independent validation
    • Frequently used as CUT&RUN IgG negative control and CUT&Tag secondary antibody
    • Used in CUT&RUN and CUT&Tag protocols, e.g. Henikoff et al. (2018) PMID 29651053, Kaya-Okur et al. (2019, 2020) PMID 31036827 and PMID 32913232

    Key Features

    • Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.529 omicron (21K).
    • Contains A67V, H69del, V70del, T95I, G142del, V143del, Y144del, Y145D, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F mutations characteristic for the SARS-CoV-2 omicron variant (B.1.1.529).

    Key Features

    • Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
    • Contains T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
    • Intact furin cleavage site 680-SRRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
    • Contains EFR157-158 deletion, T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
    • Intact furin cleavage site 680-SRRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
    • Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, and T1027I mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
    • Intact furin cleavage site 680-SPRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
    • Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
    • Intact furin cleavage site 680-SPRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
    • Contains D80A, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
    • Intact furin cleavage site 680-SPRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
    • Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
    • Intact furin cleavage site 680-SPRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
    • Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
    • Intact furin cleavage site 680-SPRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
    • Contains HV69-70 deletion, Y145 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
    • Intact furin cleavage site 680-SHRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
    • Contains HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
    • Intact furin cleavage site 680-SHRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • Recombinant SARS-CoV-2 wt S protein S1+S2 (M1-P1213) expressed in insect cells.
    • Contains D614G mutation.
    • Intact furin cleavage site 680-SPRRAR|SV-687.
    • C-terminal His-tag.

    Key Features

    • High-affinity single-domain antibody
    • Recognizes mRFP, mCherry, mScarlet-i, tdTomato, dsRed etc.
    • Bead size 50-150 μm

    Key Features

    • Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
    • Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta) and B.1.1.529 (omicron).
    • Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.

    Key Features

    • Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
    • Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta). Does NOT bind the S protein of SARS-CoV-2 B.1.1.529 (omicron).
    • Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.

    Key Features

    • Rabbit beta-Catenin antibody reliably detects beta-Catenin targets in Wnt-signaling using CUT&RUN, ICC, IF, WB, ELISA.
    • Well suited to image adherens junctions in IHC/IF.
    • Highly specific beta-Catenin detection in WB.

    Key Features

    • Rabbit anti-CRBN Antibody reliably detects CRBN in human species.
    • Polyclonal, unconjugated antibody for ELISA, WB, IHC.
    • Highly specific CRBN detection. See validation images.

    Key Features

    • Mouse IL-1 beta ELISA kit for quantitative detection of IL-1 beta.
    • Reliable product with validated components.
    • ELISA kit cited in more than 40 PubMed References.

    Key Features

    • Magnetic agarose Concanavalin A beads for affinity chromatography using a magnetic separator.
    • Easy bench-top purification of viruses, virus-like particles (VLP), and cultured cells via reversible binding of glycoproteins, glycolipids, or polysaccharides with terminal mannose or glucose to concanavalin A.

    Key Features

    • Polyclonal, unconjugated GFP antibody for reliable detection of GFP and its variants.
    • Validated for Fluorescence Microscopy, ELISA, Western Blotting
    • High Quality GFP antibody, cited in more than 177 PubMed References.
    • Available in 10 µl and 100 µl quantities.

    Key Features

    • Reliable Taurine Assay Kit for measurement of free taurine in biological samples.
    • Sample taurine concentrations are determined by comparison with a known taurine standard.
    • Quick and easy to use.

    Key Features

    • Impurity detection in the manufacturing of biological drugs.
    • The AccuSignal™ Nuclease ELISA Kit is designed for sensitive and reliable quantification of nucleases in therapeutic products, including DENARASE®, Benzonase®, and Turbonuclease.
    • Offers a broad quantification spectrum, maintaining outstanding dilution linearity, instilling trust in the accuracy of results over a wide array of nuclease concentrations.
    • Delivers consistent and repeatable outcomes, characterized by minimal intra- and inter-assay variability.
    • Tailored antibody specificity allows for application across diverse materials, accommodating various nuclease products from multiple suppliers.
    • Components: 96-well strip plate, plate sealer, nuclease standard, biotinylated detection antibody, Streptavidin-HRO (100X), buffers.

    Key Features

    • High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose magnetic beads with 50-150 µm diameter.
    • The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
    • Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.

    Key Features

    • High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
    • Highly specific for human FcRn, blocks the binding of human serum albumin.
    • PBS-only, preservative free
    • 15 PubMed references available for this FcRn antibody.

    Key Features

    • High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
    • Highly specific for human FcRn, blocks the binding of IgG.
    • PBS-only, preservative free
    • 2 PubMed references available for this FcRn antibody.

    Key Features

    • High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose beads with 50-150 µm diameter.
    • The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
    • Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.

    Key Features

    • TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
    • Manufactured by Rockland Immunochemicals, Inc.
    • Rockland Product ID: 18-8816-33

    Key Features

    • TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
    • Manufactured by Rockland Immunochemicals, Inc.
    • Rockland Product ID: 18-8816-31

    Key Features

    • Anti-ATM Protein Kinase pS1981 (MOUSE) Monoclonal Antibody
    • Manufactured by Rockland Immunochemicals, Inc.
    • Rockland Product ID: 200-301-400

    Key Features

    • High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
    • Highly specific for human FcRn, blocks the binding of human serum albumin.
    • contains Glycerol for better storage.

    Key Features

    • High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
    • Highly specific for human FcRn, blocks the binding of IgG.
    • Contains Glycerol for better storage.

    特异性

    Reacts with conformational determinants on type IV collagen Referenced species reactivities include - Human 1,12,14,27,29,31,34,36 Chicken 5,13,15 Porcine 11,22,25 Mouse 4,5,7,8,30,32 Chinchilla 17 Rabbit 5,6,14,20,23 Rat 2,3,10,26,27,33,35 Equine 18,28 Sheep 24 Bovine 5,24 Guinea Pig 14 Tree Shrew 21 Canine 9,19 Japanese Macaque 16

    交叉反应 (详细)

    Exhibits < 10 % cross reactivity with collagen type II, III, IV, V and VI. The antibody has not been tested for reactivity with other ECM proteins (e.g., laminin, fibronectin).

    产品特性

    Goat Anti-Type IV Collagen-UNLB

    纯化方法

    Purification Method: Affinity chromatography on type IV collagen covalently linked to agarose.

    亚型

    IgG

    Product Specific Information

    Our GFP Catcher is a product based on the GFP pull-down technique used to isolate GFP fusion proteins from cell lysates. It consists of special magnetic beads (product ABIN7272855) or agarose beads (product ABIN5311508) coated with an antibody against GFP. These beads allow efficient and selective binding to GFP or GFP-fused target proteins.

    The application of GFP Catcher is similar to the GFP pull-down method. First, the protein of interest is expressed in the cells with it fused to GFP. Then, the cell lysate is prepared to extract the target proteins. The GFP catcher beads are then added to the cell lysate and bound to these proteins by specifically binding to the GFP or GFP fusion protein.

    After the beads with the bound target proteins are isolated, thorough purification is performed to remove components that are not specifically bound. Finally, the target proteins can be separated from the beads and used for further analysis such as immunoblotting or mass spectrometry.

    GFP Catcher offers the advantage of quick and easy isolation of GFP fusion proteins. It is a useful tool for protein analysis and allows efficient identification of proteins interacting with GFP fusion protein. GFP Catcher is widely used in cell biology research to study protein-protein interactions and deepen the understanding of cellular processes.

  • 应用备注

    • Applications: Quality tested applications include - ELISA , FLISA
    • Other referenced applications include - IHC-PS , IHC-FS , ICC , EM , FC , WB , IP
    • Working Dilutions: ELISA BIOT conjugate 1:1,000 - 1:4,000 FLISA AF488 conjugate 1:200 - 1:400

    样本量

    0,5 mL

    限制

    仅限研究用
  • 浓度

    0.4 mg/mL

    缓冲液

    0.2 mg of purified immunoglobulin in 0.5 mL of borate buffered saline,  pH 8.2. No preservatives or amine-containing buffer salts added

    储存液

    Without preservative

    注意事项

    Each reagent is stable for the period shown on the bottle label if stored as directed.

    储存条件

    4 °C

    储存方法

    Store at 2-8°C
  • Tonello, Lee, Berta: "Monoclonal Antibody Targeting the Matrix Metalloproteinase 9 Prevents and Reverses Paclitaxel-Induced Peripheral Neuropathy in Mice." in: The journal of pain : official journal of the American Pain Society, Vol. 20, Issue 5, pp. 515-527, (2020) (PubMed).

    Zaitoun, Cikla, Zafer, Udho, Almomani, Suscha, Cengiz, Sorenson, Sheibani: "Attenuation of Retinal Vascular Development in Neonatal Mice Subjected to Hypoxic-Ischemic Encephalopathy." in: Scientific reports, Vol. 8, Issue 1, pp. 9166, (2019) (PubMed).

    Singh, Houng, Reed: "Matrix Metalloproteinase-9 Mediates the Deleterious Effects of α2-Antiplasmin on Blood-Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Stroke." in: Neuroscience, Vol. 376, pp. 40-47, (2019) (PubMed).

    Fisslthaler, Zippel, Abdel Malik, Delgado Lagos, Zukunft, Thoele, Siuda, Soehnlein, Wittig, Heidler, Weigert, Fleming: "Myeloid-Specific Deletion of the AMPKα2 Subunit Alters Monocyte Protein Expression and Atherogenesis." in: International journal of molecular sciences, Vol. 20, Issue 12, (2019) (PubMed).

    Dias, Kim, Holl, Werne Solnestam, Lundeberg, Carlén, Göritz, Frisén: "Reducing Pericyte-Derived Scarring Promotes Recovery after Spinal Cord Injury." in: Cell, Vol. 173, Issue 1, pp. 153-165.e22, (2019) (PubMed).

    Ellenbroek, de Haan, van Klarenbosch, Brans, van de Weg, Smeets, de Jong, Arslan, Timmers, Goumans, Hoefer, Doevendans, Pasterkamp, Meyaard, de Jager: "Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice." in: Scientific reports, Vol. 7, Issue 1, pp. 18039, (2019) (PubMed).

    Hu, Dziumbla, Lin, Bibli, Zukunft, de Mos, Awwad, Frömel, Jungmann, Devraj, Cheng, Wang, Fauser, Eberhart, Sodhi, Hammock, Liebner, Müller, Glaubitz, Hammes, Popp, Fleming: "Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy." in: Nature, Vol. 552, Issue 7684, pp. 248-252, (2018) (PubMed).

    Mao, Kiss, Ou, Gould: "Genetic dissection of anterior segment dysgenesis caused by a Col4a1 mutation in mouse." in: Disease models & mechanisms, Vol. 10, Issue 4, pp. 475-485, (2017) (PubMed).

    Friedrich, Bederson, Sehba: "Gender influences the initial impact of subarachnoid hemorrhage: an experimental investigation." in: PLoS ONE, Vol. 8, Issue 11, pp. e80101, (2015) (PubMed).

    Chen, Advani, Thai, Kabir, Sood, Gibson, Yuen, Connelly, Marsden, Kelly, Gilbert, Advani: "SDF-1/CXCR4 Signaling Preserves Microvascular Integrity and Renal Function in Chronic Kidney Disease." in: PLoS ONE, Vol. 9, Issue 3, pp. e92227, (2014) (PubMed).

    Mao-Ying, Kavelaars, Krukowski, Huo, Zhou, Price, Cleeland, Heijnen: "The Anti-Diabetic Drug Metformin Protects against Chemotherapy-Induced Peripheral Neuropathy in a Mouse Model." in: PLoS ONE, Vol. 9, Issue 6, pp. e100701, (2014) (PubMed).

    Wu, Davis, McMillen, Schaeffer, Zhou, Qi, Mazandarani, Alialy, Hudkins, Lusis, LeBoeuf: "Genetic modulation of diabetic nephropathy among mouse strains with Ins2 Akita mutation." in: Physiological reports, Vol. 2, Issue 11, (2014) (PubMed).

    Abrahamson, St John, Stroganova, Zelenchuk, Steenhard: "Laminin and type IV collagen isoform substitutions occur in temporally and spatially distinct patterns in developing kidney glomerular basement membranes." in: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, Vol. 61, Issue 10, pp. 706-18, (2013) (PubMed).

    Maggi, Ericson, Mascarelli, Bradley, Breitschwerdt: "Bartonella henselae bacteremia in a mother and son potentially associated with tick exposure." in: Parasites & vectors, Vol. 6, pp. 101, (2013) (PubMed).

    Mirmalek-Sani, Orlando, McQuilling, Pareta, Mack, Salvatori, Farney, Stratta, Atala, Opara, Soker: "Porcine pancreas extracellular matrix as a platform for endocrine pancreas bioengineering." in: Biomaterials, Vol. 34, Issue 22, pp. 5488-95, (2013) (PubMed).

    Manigrasso, Sawyer, Hutchens, Flynn, Maric-Bilkan: "Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats." in: American journal of physiology. Renal physiology, (2012) (PubMed).

    Manigrasso, Sawyer, Marbury, Flynn, Maric: "Inhibition of estradiol synthesis attenuates renal injury in male streptozotocin-induced diabetic rats." in: American journal of physiology. Renal physiology, Vol. 301, Issue 3, pp. F634-40, (2011) (PubMed).

    Boyette-Davis, Cata, Zhang, Driver, Wendelschafer-Crabb, Kennedy, Dougherty: "Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients." in: The journal of pain : official journal of the American Pain Society, Vol. 12, Issue 9, pp. 1017-24, (2011) (PubMed).

    Liu, Chen, Huang, Chung, Zhou, Fu, Szalai, Lan: "C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes." in: Diabetologia, Vol. 54, Issue 10, pp. 2713-23, (2011) (PubMed).

    Glorieux, Bachert, Favoreel, Vandekerckhove, Steukers, Rekecki, Van den Broeck, Goossens, Croubels, Clayton, Nauwynck: "Herpes simplex virus type 1 penetrates the basement membrane in human nasal respiratory mucosa." in: PLoS ONE, Vol. 6, Issue 7, pp. e22160, (2011) (PubMed).

  • 抗原

    Collagen IV (COL4) (Collagen, Type IV (COL4))

    别名

    Type IV Collagen
You are here:
Chat with us!